blafarm wrote: Bottom Line: We failed.>> No, b
Post# of 153822
(Total Views: 498)
Posted On: 05/26/2021 7:07:55 PM
blafarm wrote: Bottom Line: We failed.>>
No, bottom line is to find out why.
Was it Nader who designed CD12 with 2 doses? Or was it the FDA who allowed CD12 only if limited to 2 doses? Was it the Brazilians who conditioned doing CD19 on 700 ml IV followed by three 350 ml or Nader? Are you saying that Nader was supposed to cancel CD19 but not to allow the Brazilian design? Do we have many other options for doing a trial for moderately ill the way you want it?
Your bigger concern is that the company is this really powerless. Let me ask you this question: When you were buying CYDY first time did you believe this company was powerful enough to grant itself the permission to sell its product in this country and elsewhere? Or at least had enough power to exempt itself from the FDA's mandate to vet the design of clinical trials?
You want "this company and this molecule to succeed"? Are you saying Nader does want to? How about cutting your hysterics to begin helping us to succeed?
No, bottom line is to find out why.
Was it Nader who designed CD12 with 2 doses? Or was it the FDA who allowed CD12 only if limited to 2 doses? Was it the Brazilians who conditioned doing CD19 on 700 ml IV followed by three 350 ml or Nader? Are you saying that Nader was supposed to cancel CD19 but not to allow the Brazilian design? Do we have many other options for doing a trial for moderately ill the way you want it?
Your bigger concern is that the company is this really powerless. Let me ask you this question: When you were buying CYDY first time did you believe this company was powerful enough to grant itself the permission to sell its product in this country and elsewhere? Or at least had enough power to exempt itself from the FDA's mandate to vet the design of clinical trials?
You want "this company and this molecule to succeed"? Are you saying Nader does want to? How about cutting your hysterics to begin helping us to succeed?
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.